The Role of Functional Groups in Drug-Receptor Interactions

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 464-480

  Schaeffer, Laurent ^a  

^a Prestwick Chemical Inc   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864326110     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00021-4     Document Type: Chapter

References (56)

1. Klebe G., Dullweber F., Böhm H.-J. Thermodynamic models of drug-receptor interactions: a general introduction. Drug-Receptor Thermodynamics: Introduction and Applications 2001, 83-104. Wiley, Chichester. R.B. Raffa (Ed.).
2. Silverman R.B. Drug-receptor interactions. The Organic Chemistry of Drug Design and Drug Action 2004, 123-131. Elsevier Academic Press, Amsterdam.
3. Motiejunas D., Wade R.C. Structural, energetic, and dynamic aspects of ligand-receptor interactions. Comprehensive Medicinal Chemistry 2007, Vol. 4:193-213. Elsevier. J.B. Taylor, D.J. Triggle (Eds.).
4. Di Cera E. Thermodynamic Theory of Site-Specific Binding Processes in Biological Macromolecules 1995, Cambridge University Press, Cambridge.
5. Böhm H.-J., Klebe G. What can we learn from molecular recognition in protein-ligand complexes for the design of new drugs?. Angew. Chem. Int. Ed. Engl. 1996, 35:2588-2614.
6. Goldstein A., Aronow L., Kalman M.S. Principles of Drug Action. The Basis of Pharmacology 1968, 884. Hoeber Medical Division, New York.
7. Dawson R.M.C., Elliot D.C., Elliot W.H., Jones K.M. Data for Biochemical Research 1969, Oxford University Press, Oxford.
8. Paulini R., Muller K., Diederich F. Orthogonal multipolar interactions in structural chemistry and biology. Angew. Chem. Int. Ed. Engl. 2005, 44:1788-1805.
9. Bajorath J., Kraut J., Li Z.Q., Kitson D.H., Hagler A.T. Theoretical studies on the dihydrofolate reductase mechanism: electronic polarization of bound substrates. Proc. Natl. Acad. Sci. USA 1991, 88:6423-6426.
10. Jeffrey G.A. An Introduction to Hydrogen Bonding 1997, Oxford University Press, New York.
11. Stahl M., Bohm H.J. Development of filter functions for protein-ligand docking. J. Mol. Graph. Model. 1998, 16:121-132.
12. Williams M.A., Ladbury J.E. Hydrogen bonds in protein-ligand complexes. Protein-Ligand Interactions. From Molecular Recognition to Drug Design 2003, 139. Wiley-VCH, Weinheim. H.-J. Böhm, G. Schneider (Eds.).
13. Fersht A. Enzyme Structure and Mechanism 1985, Freeman, New York.
14. Fersht A. The hydrogen bond in molecular recognition. Trends Biochem. Sci. 1987, 12:301-304.
15. Knox J.R., Pratt R.F. Different modes of vancomycin and D-alanyl-D-alanine peptidase binding to cell wall peptide and a possible role for the vancomycin resistance protein. Antimicrob. Agents Chemother. 1990, 34:1342-1347.
16. Ma J.C., Dougherty D.A. The cation-π interaction. Chem. Rev. 1997, 97:1303-1324.
17. Meyer E.A., Castellano R.K., Diederich F. Interactions with aromatic rings in chemical and biological recognition. Angew. Chem. Int. Ed. Engl. 2003, 42:1210-1250.
18. Niedzwiecka A., Marcotrigiano J., Stepinski J., Jankowska-Anyszka M., Wyslouch-Cieszynska A., Dadlez M., Gingras A.C., Mak P., Darzynkiewicz E., Sonenberg N., Burley S.K., Stolarski R. Biophysical studies of eIF4E cap-binding protein: recognition of mRNA 5' cap structure and synthetic fragments of eIF4G and 4E-BP1 proteins. J. Mol. Biol. 2002, 319:615-635.
19. Schärer K., Morgenthaler M., Paulini R., Obst-Sander U., Banner D.W., Schlatter D., Benz J., Stihle M., Diederich F. Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of factor Xa bound to a quaternary ammonium ion ligand. Angew. Chem. Int. Ed. Engl. 2005, 44:4400-4404.
20. Di Fenza A., Heine A., Koert U., Klebe G. Understanding binding selectivity toward trypsin and factor Xa: the role of aromatic interactions. Chem. Med. Chem. 2007, 2:297-308.
21. Burley S.K., Petsko G.A. Weakly polar interactions in proteins. Adv. Protein Chem. 1988, 39:125-189.
22. Weichsel A., Montfort W.R. Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Nat. Struct. Biol. 1995, 2:1095-1101.
23. Dunitz J.D. Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. Chem. Biol. 1995, 2:709-712.
24. Silverstein K.A.T., Haymet A.D.J., Dill K.A. The strength of hydrogen bonds in liquid water and around nonpolar solutes. J. Am. Chem. Soc. 2000, 122:8037-8041.
25. Williams D.H., Stephens E., O'Brien D.P., Zhou M. Understanding noncovalent interactions: ligand binding energy and catalytic efficiency from ligand-induced reductions in motion within receptors and enzymes. Angew. Chem. Int. Ed. Engl. 2004, 43:6596-6616.
26. Davis A.M., Teague S.J. Hydrogen bonding, hydrophobic interactions, and failure of the rigid receptor hypothesis. Angew. Chem. Int. Ed. Engl. 1999, 38:736-749.
27. Vandonselaar M., Hickie R.A., Quail J.W., Delbaere L.T. Trifluoperazine-induced conformational change in Ca(2+)-calmodulin. Nat. Struct. Biol. 1994, 1:795-801.
28. Yu Y.B., Privalov P.L., Hodges R.S. Contribution of translational and rotational motions to molecular association in aqueous solution. Biophys. J. 2001, 81:1632-1642.
29. Page M.I. Entropy, binding energy, and enzymic catalysis. Angew. Chem. Int. Ed. Engl. 1977, 16:449-459.
30. Page M.I., Jencks W.P. Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. Proc. Natl. Acad. Sci. USA 1971, 68:1678-1683.
31. Andrews P.R., Craik D.J., Martin J.L. Functional group contributions to drug-receptor interactions. J. Med. Chem. 1984, 27:1648-1657.
32. Gohlke H., Klebe G. Approaches to the description and prediction of the binding affinity of small-molecule ligands to macromolecular receptors. Angew. Chem. Int. Ed. Engl. 2002, 41:2644-2676.
33. Lau W.F., Pettitt B.M. Selective elimination of interactions: a method for assessing thermodynamic contributions to ligand binding with application to rhinovirus antivirals. J. Med. Chem. 1989, 32:2542-2547.
34. Jencks W.P. On the attribution and additivity of binding energies. Proc. Natl. Acad. Sci. USA 1981, 78:4046-4050.
35. Andrews P.R. 3D QSAR in drug design: theory, methods and applications 1993, 13-40. ESCOM Science Publishers B.V., Leiden. H. Kubinyi (Ed.).
36. Williams D.H., Cox J.P.L., Doig A.J., Gardner M., Gerhard U., Kaye P.T., Lal A.L., Nichols I.A., Salter C.J., Mitchell R.C. Toward the semiquantitative estimation of binding constants. Guides for peptide-peptide binding in aqueous solution. J. Am. Chem. Soc. 1991, 113:7020-7030.
37. Searle M.S., Williams D.H. The cost of conformational order: Entropy changes in molecular associations. J. Am. Chem. Soc. 1992, 114:10690-10697.
38. Böhm H.J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des. 1994, 8:243-256.
39. Wolfenden R., Kati W.M. Testing the limits of protein-ligand binding discrimination with transition-state analogue inhibitors. Acc. Chem. Res. 1991, 24:209-215.
40. Kati W.M., Wolfenden R. Contribution of a single hydroxyl group to transition-state discrimination by adenosine deaminase: evidence for an "entropy trap" mechanism. Biochemistry 1989, 28:7919-7927.
41. Wilson D.K., Rudolph F.B., Quiocho F.A. Atomic structure of adenosine deaminase complexed with a transition-state analog: understanding catalysis and immunodeficiency mutations. Science 1991, 252:1278-1284.
42. Fersht A.R., Shi J.P., Knill-Jones J., Lowe D.M., Wilkinson A.J., Blow D.M., Brick P., Carter P., Waye M.M., Winter G. Hydrogen bonding and biological specificity analysed by protein engineering. Nature 1985, 314:235-238.
43. Levine D., Reid T.W., Wilson I.B. The free energy of hydrolysis of the phosphoryl-enzyme intermediate in alkaline phosphatase catalyzed reactions. Biochemistry 1969, 8:2374-2480.
44. Northrop D.B., Wood H.G. Transcarboxylase. VII. Exchange reactions and kinetics of oxalate inhibition. J. Biol. Chem. 1969, 244:5820-5827.
45. Hirsch A.K., Fischer F.R., Diederich F. Phosphate recognition in structural biology. Angew. Chem. Int. Ed. Engl. 2007, 46:338-352.
46. Colman P.M. The influenza virus 1989, 175-218. Plenum Press, New York. R.M. Krug (Ed.).
47. von Itzstein M., Wu W.-Y., Kok G.B., Pegg M.S., Dyason J.C., Jin B., Phan T.V., Smythe M.L., White H.F., Oliver S.W., Colman P.M., Varghese J.N., Ryan D.M., Woods J.M., Bethell R.C., Hotham V.J., Cameron J.M., Penn C.R. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993, 363:418-423.
48. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9:430-431.
49. Abad-Zapatero C., Metz J.T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 2005, 10:464-469.
50. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc. Natl. Acad. Sci. USA 1999, 96:9997-10002.
51. Abad-Zapatero C. Ligand efficiency indices for effective drug discovery. Expert Opinion on Drug Discovery 2007, 2:469-488.
52. Reynolds C.H., Bembenek S.D., Tounge B.A. The role of molecular size in ligand efficiency. Bioorg. Med. Chem. Lett. 2007, 17:4258-4261.
53. Leach A.R., Hann M.M., Burrows J.N., Griffen E.J. Fragment screening: an introduction. Mol. Biosyst. 2006, 2:430-446.
54. Calderone C.T., Williams D.H. An enthalpic component in cooperativity: the relationship between enthalpy, entropy, and noncovalent structure in weak associations. J. Am. Chem. Soc. 2001, 123:6262-6267.
55. Williams D.H., Davies N.L., Zerella R., Bardsley B. Noncovalent interactions: defining cooperativity. Ligand binding aided by reduced dynamic behavior of receptors. Binding of bacterial cell wall analogues to ristocetin A. J. Am. Chem. Soc. 2004, 126:2042-2049.
56. DeChancie J., Houk K.N. The origins of femtomolar protein-ligand binding: hydrogen-bond cooperativity and desolvation energetics in the biotin-(strept)avidin binding site. J. Am. Chem. Soc. 2007, 129:5419-5429.